跳至主要内容
临床试验/PACTR202001787519553
PACTR202001787519553招募中未知

ow dose aspirin for preventing intrauterine growth restriction and preeclampsia in sickle cell pregnancy (PIP-SICKLE): a randomised controlled trial.

TETFUND0 个研究点目标入组 476 人开始时间: 2019年10月4日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
TETFUND
入组人数
476

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
19 Year(s) 至 44 Year(s)(—)
性别
Female

入选标准

  • Age 18 years and above
  • Singleton fetus
  • Women with sickle cell anaemia i.e. Haemoglobin SS.
  • 16 weeks gestation or less at recruitment, confirmed by an ultrasound scan or certain last menstrual period dates

排除标准

  • Other sickle cell disease variants eg Hb SC
  • Women with associated medical conditions in pregnancy eg HIV infection, diabetes mellitus, chronic hypertension, renal disease, sickle nephropathy
  • Women with multiple pregnancy
  • Hypersensitivity to aspirin
  • History of vaso-occlusive crisis in the last 4 weeks
  • History of blood transfusion in the last 3 months

研究者

发起方
TETFUND

相似试验